Veterans Aging Cohort Study (VACS) 2.0 Index
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۰ — حداکثر ۲۰۰۰ • واحد: cells/μL
حداقل ۰ — حداکثر ۷ • واحد: log10 copies/mL
حداقل ۵ — حداکثر ۲۰ • واحد: g/dL
حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10³/μL
حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L
حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L
حداقل ۰.۵ — حداکثر ۱۰ • واحد: mg/dL
حداقل ۱ — حداکثر ۶ • واحد: g/dL
حداقل ۱ — حداکثر ۵۰ • واحد: ×10³/μL
حداقل ۱۰ — حداکثر ۵۰ • واحد: kg/m²
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–25
- Moderate Risk26–50
- High Risk51–75
- Very High Risk76–164
The Veterans Aging Cohort Study (VACS) 2.0 Index calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates 5-year all-cause mortality risk in patients with HIV using age, HIV-specific biomarkers, and general health indicators. An improved version of the original VACS Index with enhanced discrimination.
Clinical Indication
The Veterans Aging Cohort Study (VACS) 2.0 Index is indicated for bedside clinical practice to support Estimates 5-year all-cause mortality risk in patients with HIV using age, HIV-specific biomarkers, and general health indicators. An improved version of the original VACS Index with enhanced discrimination.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
VACS 2.0 = f(Age, CD4, HIV RNA, Hemoglobin, FIB-4, eGFR, Albumin, WBC, BMI, HCV) where FIB-4 = (Age × AST) / (Platelets × √ALT) and eGFR calculated using CKD-EPI equation
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years(years) |
| sex | string | Yes | Patient sex for eGFR calculation |
| race | string | Yes | Patient race for eGFR calculation |
| cd4_count | integer | Yes | CD4 T-cell count (cells/μL)(cells/μL) |
| hiv_rna_log | float | Yes | HIV-1 RNA viral load (log10 copies/mL)(log10 copies/mL) |
| hemoglobin | float | Yes | Hemoglobin level (g/dL)(g/dL) |
| platelets | integer | Yes | Platelet count (×10³/μL)(×10³/μL) |
| ast | integer | Yes | Aspartate aminotransferase (U/L)(U/L) |
| alt | integer | Yes | Alanine aminotransferase (U/L)(U/L) |
| creatinine | float | Yes | Serum creatinine (mg/dL)(mg/dL) |
| albumin | float | Yes | Serum albumin (g/dL)(g/dL) |
| wbc_count | float | Yes | White blood cell count (×10³/μL)(×10³/μL) |
| bmi | float | Yes | Body mass index (kg/m²)(kg/m²) |
| hepatitis_c | string | Yes | Hepatitis C virus co-infection status |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–25 | Low Risk | Low 5-year mortality risk |
| 26–50 | Moderate Risk | Moderate 5-year mortality risk |
| 51–75 | High Risk | High 5-year mortality risk |
| 76–164 | Very High Risk | Very high 5-year mortality risk |
Evidence-Based References (EBM)
- Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency virus infection: A comparison of disease measurement strategies. Med Care. 2006;44(8 Suppl 2):S52-60.
- Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med. 2010;11(2):143-51.
- Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563-72.
- Justice AC, Erlandson KM, Hunt PW, et al. Development and validation of a prognostic index for 1-year mortality in HIV-infected adults. Med Care. 2013;51(12):1054-64.
- Rodriguez-Barradas MC, Tate JP, Justice AC, et al. Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. AIDS. 2019;33(6):903-912.